Table 2.
Effect of onset-treatment with SHSST on a subsequent encephalogenic challenge.
| Group | Incidence (%) | Mean day of onset (±SEM) | Maximal clinical score (±SEM) | Sum of clinical score (±SEM) | Mortality (%) | |
|---|---|---|---|---|---|---|
| Onset- | Sham | 3/3 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0 |
| EAE | 5/5 | 7.2 ± 0.2 | 4.0 ± 0.0## | 80.2 ± 0.8## | 0 | |
| EAE + SHSST 300 mg/kg | 5/5 | 7.2 ± 0.2 | 3.6 ± 0.2 | 57.6 ± 2.0∗ | 0 | |
| EAE + SHSST 600 mg/kg | 5/5 | 7.6 ± 0.6 | 2.2 ± 0.2∗ | 35.2 ± 1.9∗∗ | 0 | |
| Pre- | Sham | 3/3 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0 |
| EAE | 6/6 | 7.8 ± 0.3 | 4.0 ± 0.0## | 73.3 ± 1.4## | 0 | |
| EAE + SHSST 600 mg/kg | 6/6 | 10.8 ± 1.0 | 2.7 ± 0.2∗ | 40.8 ± 2.6∗ | 0 | |
| Post- | Sham | 3/3 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0 |
| EAE | 6/6 | 8.2 ± 0.5 | 3.5 ± 0.2# | 58.7 ± 3.2## | 0 | |
| EAE + SHSST 600 mg/kg | 6/6 | 8.2 ± 0.5 | 3.5 ± 0.2 | 56.7 ± 2.2 | 0 |
Data are expressed as mean ± SEM. (ANOVA testing was performed; #p < 0.05 and ##p < 0.01 versus the sham group; ∗p < 0.05 and ∗∗p < 0.01 versus the EAE group.)